BR0009675A - Métodos adequado para tipificar prpsc e de alterar a conformação de prpsc, uso de um agente capaz de afetar a ligação de prpsc a um ou mais ìons metálicos divalentes, métodos de triar para um agente capaz de alterar a conformação do prpsc tipo 1 e/ou tipo 2 e de triar para um agente para uso na prevenção diagnóstico e/ou tratamento de uma doença de prion, uso de um agente obtenìvel por um método, kit, prpsc isolado tipo 2, e, uso de prpsc isolado tipo 2 - Google Patents

Métodos adequado para tipificar prpsc e de alterar a conformação de prpsc, uso de um agente capaz de afetar a ligação de prpsc a um ou mais ìons metálicos divalentes, métodos de triar para um agente capaz de alterar a conformação do prpsc tipo 1 e/ou tipo 2 e de triar para um agente para uso na prevenção diagnóstico e/ou tratamento de uma doença de prion, uso de um agente obtenìvel por um método, kit, prpsc isolado tipo 2, e, uso de prpsc isolado tipo 2

Info

Publication number
BR0009675A
BR0009675A BR0009675-0A BR0009675A BR0009675A BR 0009675 A BR0009675 A BR 0009675A BR 0009675 A BR0009675 A BR 0009675A BR 0009675 A BR0009675 A BR 0009675A
Authority
BR
Brazil
Prior art keywords
prpsc
type
agent
conformation
screening
Prior art date
Application number
BR0009675-0A
Other languages
English (en)
Inventor
John Collinge
Jonathan David Frank Wadsworth
Original Assignee
D Gen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D Gen Ltd filed Critical D Gen Ltd
Publication of BR0009675A publication Critical patent/BR0009675A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)

Abstract

"MéTODOS ADEQUADO PARA TIPIFICAR PrP^ sc^ E DE ALTERAR A CONFORMAçãO DE PrP^ sc^, USO DE UM AGENTE CAPAZ DE AFETAR A LIGAçãO DE PrP^ sc^ A UM OU MAIS ìONS METáLICOS DIVALENTES, MéTODOS DE TRIAR PARA UM AGENTE CAPAZ DE ALTERAR A CONFORMAçãO DO PrP^ sc^ TIPO 1 E/OU TIPO 2 E DE TRIAR PARA UM AGENTE PARA USO NA PREVENçãO DIAGNóSTICA E/OU TRATAMENTO DE UMA DOENçA DE PRION, USO DE UM AGENTE OBTENìVEL POR UM MéTODO, KIT, PrP^ sc^ ISOLADO TIPO 2-, E, USO DE PrP^ sc^ ISOLADO TIPO 2^ -^". Esta invenção refere-se a métodos e materiais para uso na tipificação, diagnóstico, prevenção e/ou tratamento de doença de prion.
BR0009675-0A 1999-04-09 2000-04-07 Métodos adequado para tipificar prpsc e de alterar a conformação de prpsc, uso de um agente capaz de afetar a ligação de prpsc a um ou mais ìons metálicos divalentes, métodos de triar para um agente capaz de alterar a conformação do prpsc tipo 1 e/ou tipo 2 e de triar para um agente para uso na prevenção diagnóstico e/ou tratamento de uma doença de prion, uso de um agente obtenìvel por um método, kit, prpsc isolado tipo 2, e, uso de prpsc isolado tipo 2 BR0009675A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9908059.0A GB9908059D0 (en) 1999-04-09 1999-04-09 Diagnosis and treatment of diseases
PCT/GB2000/001327 WO2000062068A1 (en) 1999-04-09 2000-04-07 Method to type prion proteins

Publications (1)

Publication Number Publication Date
BR0009675A true BR0009675A (pt) 2002-03-26

Family

ID=10851181

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009675-0A BR0009675A (pt) 1999-04-09 2000-04-07 Métodos adequado para tipificar prpsc e de alterar a conformação de prpsc, uso de um agente capaz de afetar a ligação de prpsc a um ou mais ìons metálicos divalentes, métodos de triar para um agente capaz de alterar a conformação do prpsc tipo 1 e/ou tipo 2 e de triar para um agente para uso na prevenção diagnóstico e/ou tratamento de uma doença de prion, uso de um agente obtenìvel por um método, kit, prpsc isolado tipo 2, e, uso de prpsc isolado tipo 2

Country Status (9)

Country Link
US (1) US6887676B1 (pt)
EP (1) EP1169644A1 (pt)
JP (1) JP2002541480A (pt)
AU (1) AU773102B2 (pt)
BR (1) BR0009675A (pt)
CA (1) CA2369629A1 (pt)
GB (1) GB9908059D0 (pt)
NZ (1) NZ514691A (pt)
WO (1) WO2000062068A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230838B4 (de) * 2002-07-04 2005-02-03 Mediquant Gmbh Diagnostische Verwendung von pharmazeutischen Substanzen
FR2865280B1 (fr) * 2004-01-20 2007-01-12 Biomerieux Sa Procede de detection de la prp utilisant une molecule ayant au moins une charge positive et/ou au moins une liaison osidique et un ligand autre qu'un ligand proteique
EP1571449A1 (en) * 2004-03-01 2005-09-07 Stichting Sanquin Bloedvoorziening Prion immunoassay and separation method
FR2870458B1 (fr) * 2004-05-24 2008-10-03 Centre Nat Rech Scient Cnrse Produits et procede pour la decontamination des prions
FR2888937B1 (fr) * 2005-07-21 2012-10-26 Biomerieux Sa Procede de detection des fcpa utilisant un agent d'agregation des fcpa et un agent de capture des agregats formes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268904A1 (en) * 1996-10-15 1998-04-23 Imperial College Of Science, Technology And Medicine Diagnosis of spongiform encephalopathy
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
US6214366B1 (en) * 1999-06-01 2001-04-10 The Regents Of The University Of California Clearance and inhibition of conformationally altered proteins
US6617119B2 (en) * 1997-02-21 2003-09-09 The Regents Of The University Of California Assay for specific strains of multiple disease related conformations of a protein

Also Published As

Publication number Publication date
JP2002541480A (ja) 2002-12-03
CA2369629A1 (en) 2000-10-19
GB9908059D0 (en) 1999-06-02
AU3829100A (en) 2000-11-14
AU773102B2 (en) 2004-05-13
EP1169644A1 (en) 2002-01-09
WO2000062068A1 (en) 2000-10-19
NZ514691A (en) 2004-02-27
US6887676B1 (en) 2005-05-03

Similar Documents

Publication Publication Date Title
WO2001098317A3 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
BRPI0411552A (pt) anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
CA2345024A1 (en) Modified tgf-.beta. superfamily proteins
WO2003055443A3 (en) Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
AU2002366641A1 (en) Methods for inhibiting ocular processes
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
IL172646A0 (en) Antibodies against interleukin -22 and uses therefor
WO2005068503A3 (en) M-csf-specific monoclonal antibody and uses thereof
BR9607846B1 (pt) métodos de seleção de agentes que modulam ou inibem associação de tau-tau, ou revertem toxicidade na célula de tau agregado.
IL184617A (en) Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
BRPI0415397A (pt) métodos e reagentes para o tratamento de desordens imunoinflamatórias
EA200100822A1 (ru) Baff, относящиеся к нему блокирующие агенты и их применение в стимуляции и ингибировании b-клеток и иммуноглобулинов в иммунных реакциях
WO2002085285A3 (en) Methods and reagents for regulating bone and cartilage formation
SI1608399T1 (sl) Kompleks sklerostina in noggina ali chordina in sredstva ki modulirajo tvorbo navedenega kompleksa
ATE253554T1 (de) 1alpha-hydroxy-25-ene-vitamin d, deren analogen und verwendung davon
IL189629A0 (en) Compositions containing human ctla-4 antibodies
GB0315450D0 (en) Biological products
CO4910133A1 (es) Antagonistas de 5-h[1f]
BRPI0413495A (pt) reagentes de peptìdeos especìficos para prìons e seus usos
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
ATE483806T1 (de) Polynukleotide, welche für mitglieder der humanen b lymphozyten-aktivierendes antigen familie kodieren, und von diesen kodierte polypeptide
BR0009675A (pt) Métodos adequado para tipificar prpsc e de alterar a conformação de prpsc, uso de um agente capaz de afetar a ligação de prpsc a um ou mais ìons metálicos divalentes, métodos de triar para um agente capaz de alterar a conformação do prpsc tipo 1 e/ou tipo 2 e de triar para um agente para uso na prevenção diagnóstico e/ou tratamento de uma doença de prion, uso de um agente obtenìvel por um método, kit, prpsc isolado tipo 2, e, uso de prpsc isolado tipo 2
WO2004007531A3 (en) Activated checkpoint therapy and methods of use thereof
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1925 DE 27/11/2007.